HDAC9 and neoplasm: Histone deacetylases (HDACs) deacetylate both histone proteins and non-histone cellular substrates that govern a wide array of disease processes including tumour progression and tumour therapy, and HDAC inhibitors are a staple of cancer treatment [35, 36].